The appraisal committee has prepared final draft guidance (FDG) on targeted-release budesonide for treating primary IgA nephropathy and submitted it to NICE.
The FDG has been sent to consultees for this appraisal who have 5 working days to advise if they wish to appeal against it and/or notify us of any factual errors. If an intent to appeal is submitted the consultees will have an additional 10 working days to submit their appeal. The FDG has been sent to commentators for information, who can consider notifying us of any factual errors only. Subject to any appeal by consultees, the FDG may be used as the basis for NICE's guidance on the use of the appraised technology in the NHS in England.
Please note that the intentions to appeal for this appraisal must be submitted by 5pm, Thursday 22 January 2026.
Resource impact tools
The resource impact team have prepared the resource impact tools (excel template and summary report) to support implementation of the final draft guidance (FDG) on targeted release budesonide for treating primary IgA nephropathy (review of TA937) [ID6485].
- Resource impact summary report (downloadable version)
- Resource impact template (downloadable version)
- Resource impact comments table (downloadable version)
During the 5 day appeal period of the FDG, you can send any comments on the tools using the consultation table form and emailing them to ResourceImpactAssessment@nice.org.uk
The deadline is 29 January 2026
This page was last updated: